RecruitingPhase 1

Study of NTB-928 in R/R OC

United States90 participantsStarted 2026-06-29

Plain-language summary

The goal of this clinical trial is to determine if NTB-928 can be given safely to adult females with ovarian cancer that has come back (relapsed) or stopped responding to treatment (refractory), how NTB-928 moves through the body, and how the immune system reacts to it. The study will also look for early signs of anti-cancer activity of NTB-928. The main questions the study aims to answer are: * What side effects do participants experience when receiving NTB-928, including side effects that limit how much of it can be safely given? * How is NTB-928 processed by the body at different dose levels? * Does the immune system react to NTB-928 during treatment? * What dose of NTB-928 can be given safely that shows early signs of activity against ovarian cancer?

Who can participate

Age range

18 Years

Sex

FEMALE

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Aged 18 years or older * Have a confirmed diagnosis of ovarian cancer, including high-grade serous, high-grade endometrioid, low-grade serous, or clear cell ovarian cancer, or carcinosarcoma of the ovary. Patients with mucinous carcinoma are not eligible. * Have relapsed or refractory ovarian cancer and have already received standard treatments known to provide benefit; participants are eligible if they have platinum-refractory, platinum-resistant, or platinum-sensitive ovarian cancer (with clearly documented ineligibility for further platinum chemotherapy). * Are able to understand the study requirements and are willing to provide written informed consent * Are willing to use effective birth control during the study and for a period after the last dose of study treatment, if of childbearing potential Exclusion Criteria: * Have another active cancer that could interfere with assessment of this study treatment * Have received another investigational drug or certain cancer treatments within a recent period before starting this study * Are pregnant or breastfeeding

Questions worth asking your doctor

Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.

1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?

Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.

Questions for the trial coordinator

The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.

1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?

A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.

What they're measuring

Number of dose-limiting toxicities (DLTs) within the first cycle of treatment with NTB-928

Timeframe: Up to 35 days

Number of participants with adverse events (AEs) and serious adverse events (SAEs), by severity and relatedness to NTB-928

Timeframe: Up to approximately 3 years

Maximum plasma concentration (Cmax)

Timeframe: Up to approximately 3 years

Time to Cmax (Tmax)

Timeframe: Up to approximately 3 years

Area under the plasma concentration-time curve (AUC) over the dosing interval (AUC0-T)

Timeframe: Up to approximately 3 years

AUC from time zero to time t (AUC0-t)

Timeframe: Up to approximately 3 years

AUC from time 0 extrapolated to infinity (AUC0-∞)

Timeframe: Up to approximately 3 years

Trial details

NCT IDNCT07690189

SponsorTeneoSeven, Inc.

Sponsor typeINDUSTRY

Study typeINTERVENTIONAL

Primary completion2028-06

Contact for this trial

Clinical Trial Information

510-392-0929 clinicaltrial@92biotech.com

View on ClinicalTrials.gov More Relapsed/Refractory Ovarian Carcinoma trials

Plain-language summary

Who can participate

Age range

18 Years

Sex

FEMALE

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

What they're measuring

Number of dose-limiting toxicities (DLTs) within the first cycle of treatment with NTB-928

Timeframe: Up to 35 days

Number of participants with adverse events (AEs) and serious adverse events (SAEs), by severity and relatedness to NTB-928

Timeframe: Up to approximately 3 years

Maximum plasma concentration (Cmax)

Timeframe: Up to approximately 3 years

Time to Cmax (Tmax)

Timeframe: Up to approximately 3 years

Area under the plasma concentration-time curve (AUC) over the dosing interval (AUC0-T)

Timeframe: Up to approximately 3 years

AUC from time zero to time t (AUC0-t)

Timeframe: Up to approximately 3 years

AUC from time 0 extrapolated to infinity (AUC0-∞)

Timeframe: Up to approximately 3 years